Skip to content
Screener

Amgen AMGN Finite Lived Intangible Assets - Gross

Finite Lived Intangible Assets - Gross at other companies

Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$30.36M
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$8.1B+2.5%

Other financials

Income statement

See full
Revenue$10.1B+9.5%
Gross profit$7.2B+17.4%
Operating income$3.5B+32.3%
Net income$2.4B+65.9%
EPS (diluted)$4.37+64.9%

Balance sheet

See full
Cash & equivalents$574.0M+5.9%
Total debt$57.3B+2.0%
Total equity$11.7B+57.4%
Total assets$95.6B+8.8%

Cash flow

See full
Operating cash flow$4.0B+75.5%
CapEx$513.0M+39.0%
Free cash flow$3.5B+82.6%

Valuation

See full
Market cap$220.64B+44.0%
Enterprise value$277.37B+32.8%
P/E25.2×+2.1×
P/S5.8×+1.4×

Profitability

See full
Gross margin69.5%+5.0pp
Operating margin30%+6.5pp
Net margin23%+4.0pp
FCF margin26.7%-3.7pp

Returns & leverage

See full
Return on equity91.5%-7.7pp
Debt / equity4.9×-2.7×
Current ratio1.4×+0.1×

Where this comes from

Reported directly by Amgen in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsGross.

The source filing: Amgen’s 10-Q, filed August 5, 2026.

Filed
Aug 4, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000318154-26-000126
Line itemJune 30, 2026 / GrosscarryingamountsJune 30, 2026 / AccumulatedamortizationJune 30, 2026 / Other intangibleassets, netDecember 31, 2025 / GrosscarryingamountsDecember 31, 2025 / AccumulatedamortizationDecember 31, 2025 / Other intangibleassets, net
Developed-product-technology rights$47,793$(28,450)$19,343$47,805$(26,754)$21,051
Licensing rights3,902(3,573)3293,917(3,522)395
Research and development technology rights1,409(1,304)1051,425(1,305)120
Marketing-related rights1,202(1,202)1,203(1,203)
Total finite-lived intangible assets54,306(34,529)19,77754,350(32,784)21,566
Indefinite-lived intangible assets:
In-process research and development710710710710
Total other intangible assets$55,016$(34,529)$20,487$55,060$(32,784)$22,276

Item 1. FINANCIAL STATEMENTS

FAQ

What is Amgen's finite lived intangible assets - gross?
Amgen (AMGN) reported finite lived intangible assets - gross of $54.31B in Q2 2026.
How has Amgen's finite lived intangible assets - gross changed year-over-year?
Amgen's finite lived intangible assets - gross decreased by 0.7% year-over-year, from $54.7B to $54.31B.
What is the long-term trend for Amgen's finite lived intangible assets - gross?
Over 5 years (2020 to 2025), Amgen's finite lived intangible assets - gross has grown at a 11.2% compound annual growth rate (CAGR), from $32.02B to $54.35B.
What does finite lived intangible assets - gross mean?
This metric tracks the total historical cost of intangible assets that have a defined useful life, such as patents, software licenses, or customer relationships. It excludes assets with indefinite lives like certain trademarks or goodwill. It is a key indicator of the company's investment in intellectual property and intangible competitive advantages.

Ask your AI about Amgen's finite lived intangible assets - gross.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude